| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Ceritinib |
| Brand | Zykadia® |
| Indication | For the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. |
| Assessment Process | |
| Rapid review commissioned | 29/05/2015 |
| Rapid review completed | 22/07/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations.